Beam Therapeutics Inc. Annual cash flow by MarketWatch. View BEAM net cash flow, operating cash flow, operating expenses and cash dividends.
Analysts have set 12-month price targets for Beam Therapeutics, revealing an average target of $44.5, a high estimate of $74.00, and a low estimate of $28.00. This current average reflects an increase ...
Beam Therapeutics Inc. Annual cash flow by MarketWatch. View BEAM net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results